NCT06122987View on ClinicalTrials.gov

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2025

Conditions
Septic ShockShockSepsisSystemic Inflammatory Response Syndrome
Interventions
DRUG

Angiotensin II and hydrocortisone sodium succinate

Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.

Trial Locations (1)

86401

RECRUITING

Kingman Regional Medical Center, Kingman

Sponsors
All Listed Sponsors
collaborator

La Jolla Pharmaceutical Company

INDUSTRY

lead

Kingman Regional Medical Center

OTHER

NCT06122987 - Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock | Biotech Hunter | Biotech Hunter